JBT Marel (JBTM) Q2 2026 earnings review
Protein Strength Masks Supply Chain Friction
JBT Marel posted a mixed Q2. The overarching story is a tale of two segments: Protein Solutions is booming with 24% margins and 11% sales growth, while Prepared Food & Beverage (PF&B) is stalling under the weight of logistics constraints and operational inefficiencies. A third consecutive quarter of >$1 billion in orders pushes the backlog to a record $1.54 billion, proving the top-line thesis of the merger is intact. However, management quietly lowered their Adjusted EPS guidance and absorbed a $33 million impairment charge, signaling that post-merger execution is not without its speed bumps.
🐂 Bull Case
The company booked $1.03 billion in orders with a book-to-bill ratio of 1.05x. A record $1.54 billion backlog essentially guarantees strong revenue visibility through the end of 2026.
Protein Solutions grew revenue by 11% YoY and expanded Adjusted EBITDA margins by a massive 350 basis points to 24.0%. Favorable mix and continuous improvement are paying off.
🐻 Bear Case
Prepared Food & Beverage revenue was totally flat YoY. Margins fell 70 basis points YoY as the company struggled with logistics constraints and factory inefficiencies.
Despite strong top-line numbers, Adjusted EPS guidance was revised downward. Combined with a surprise $33 million impairment charge, it raises questions about underlying earnings quality.
⚖️ Verdict: ⚪
Neutral. The commercial momentum and synergy savings are highly impressive, but operational missteps in half the business and a reduced EPS outlook cap the upside. Execution must become more consistent.
Key Themes
Protein Solutions Leading the Charge
The Protein Solutions segment continues to accelerate, generating $467 million in revenue (+11% YoY) and an Adjusted EBITDA margin of 24.0%. Management explicitly tied this strength to downstream, further processing technology investments. As customers complete primary processing upgrades, they are heavily investing in value-added product lines (like nuggets and patties), playing directly into JBT Marel's integrated portfolio strength.
Prepared Food & Beverage Sputters on Execution
The PF&B segment is decelerating. Revenue was completely flat at $514 million. Management blamed 'timing of backlog-to-revenue conversion resulting from logistics constraints' and 'productivity inefficiencies.' While sequential margin improved from Q1's dismal 14.7% to 17.5% in Q2, it still lags the 18.3% achieved a year ago. The carry-over of warehouse automation weakness noted in Q1 appears to be dragging down broader segment efficiency.
Guidance Cut Contradicts 'Visibility' Narrative
Management touted a 'record backlog' providing 'visibility into our second half'—yet simultaneously cut the Adjusted EPS guidance midpoint by $0.15. The given reason is 'updated assumptions for depreciation and amortization expense and the effective tax rate.' While non-operational, cutting earnings targets while boasting about demand highlights a disconnect between top-line growth and bottom-line delivery.
Rapid Deleveraging on Track
JBT Marel is generating significant cash to aggressively pay down post-merger debt. Free cash flow for the first half of 2026 hit $179 million, bringing the net debt to trailing twelve months Adjusted EBITDA ratio down to 2.47x (Bank leverage at 2.40x). This places the company comfortably within its long-term target leverage range of 2.0x - 2.5x six months ahead of schedule, opening the door for capital return flexibility.
Cost Synergies Flowing to Bottom Line
The company remains highly confident in recognizing $60 million of in-year realized synergy savings for 2026. This is the primary mechanism shielding consolidated Adjusted EBITDA margins (up 40 bps to 17.1%) from the localized inflation and operational pain occurring in the PF&B segment.
Macro Pressures: Inflation and Tariffs Squeeze Operations
Macroeconomic headwinds are not abating. Management specifically highlighted navigating a 'dynamic operating environment with higher inflationary costs' alongside supply chain optimization struggles. Prior quarters highlighted 25-50 bps of tariff headwinds across the year; Q2 results confirm these external pressures are forcing the company to lean heavily on internal pricing actions and synergy extraction just to hold margins steady.
Sudden $33M Impairment Charge
Net income margin guidance was significantly impacted by a sudden $33 million non-cash, non-recurring impairment charge related to a 2021 legacy acquisition. Management did not specify which asset failed the impairment test in the press release, but sudden write-downs reflect poor historical capital allocation and require explanation on the upcoming earnings call.
Other KPIs
Accelerating significantly. YTD FCF reached $179 million compared to $106 million in the same period last year. This 69% increase is driven by higher operating cash flow ($221M vs $137M) despite higher net working capital requirements for inventory ($700M balance). Superb conversion.
Stable and compounding. Up $12 million YoY, reflecting an adjusted EBITDA margin of 17.1% (a 40 bps YoY improvement). The bulk of this heavy lifting was done entirely by the Protein Solutions segment, offsetting flat/declining performance elsewhere.
Guidance
Stable. The company reiterated its expectation for 5-7% consolidated revenue growth, including an approximate 1.5% foreign exchange translation benefit. With $1.91 billion booked in H1, they need just over $2.1 billion in H2, supported heavily by the $1.54B backlog.
Stable. Reaffirming this target implies that management expects the second half of the year to look very similar to Q2 (17.1%), relying on the $60 million in-year cost synergies to outpace persistent inflation and PF&B logistics snags.
Decelerating. Management refined this downward from previous commentary (which hovered around $8.00 - $8.50 earlier in the year). The adjustment is due to updated, higher assumptions for depreciation and amortization expense ($263 million) and a 24% effective tax rate.
Decelerating. Revised downward primarily to reflect the sudden $33 million non-cash impairment charge incurred during Q2.
Key Questions
PF&B Logistics Breakdown
You cited logistics constraints and productivity inefficiencies in Prepared Food & Beverage this quarter. Are these issues localized to specific facilities, or tied to the lingering warehouse automation issues from Q1? What is the timeline for resolution?
Details on the Impairment
Can you provide specifics on the $33 million non-cash impairment charge related to a 2021 acquisition? Which business was written down, and what structural changes in its end-market triggered this test?
Adjusted EPS Trim
Despite strong orders and reaffirmed EBITDA targets, Adjusted EPS guidance was trimmed due to higher D&A and tax rates. Can you unpack the mechanics driving higher D&A sequentially?